---
title: "Dongyao Pharmaceutical's net loss for the fiscal year 2025 is 100 million RMB"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277639243.md"
description: "Dongyao Pharmaceutical - B announced its unaudited financial data for the fiscal year 2025, with operating revenue of 748 million RMB, a year-on-year decrease of 31.9%. It recorded a net loss of 100 million RMB, compared to a net profit of 34.76 million RMB in the previous year, turning from profit to loss"
datetime: "2026-03-03T14:34:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277639243.md)
  - [en](https://longbridge.com/en/news/277639243.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277639243.md)
---

# Dongyao Pharmaceutical's net loss for the fiscal year 2025 is 100 million RMB

Dongyao Pharmaceutical-B (01875.HK) announced its unaudited financial data for the fiscal year 2025, with operating revenue of 748 million RMB, a year-on-year decrease of 31.9%. It recorded a net loss of 100 million RMB, compared to a net profit of 34.76 million RMB in the previous year, turning from profit to loss

### Related Stocks

- [01875.HK](https://longbridge.com/en/quote/01875.HK.md)

## Related News & Research

- [AcouSort announces availability of fiscal 2025 annual report](https://longbridge.com/en/news/287066264.md)
- [RUSAL Board Recommends No Dividend for 2025 Results](https://longbridge.com/en/news/286485783.md)
- [Bio-Gate publishes 2025 annual report](https://longbridge.com/en/news/287059650.md)
- [Lingbao Gold Wins Shareholder Backing for 2025 Reports and New Capital Mandates](https://longbridge.com/en/news/286919537.md)
- [UK 10-year bonds head for sharpest daily slump since April 2025](https://longbridge.com/en/news/286568738.md)